Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Faces Skeptical Judge In Bid To Undo Teva Provigil Generic Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

During more than two-and-a-half hours of oral arguments, Judge Ellen Huvelle repeatedly asked Mylan’s counsel how the Hatch-Waxman Act gives her the power to order FDA to take modafinil 180-day exclusivity rights away from Teva. However, the judge also expressed “deep concern” that Teva would challenge FDA’s trigger decision and further delay other ANDA filers from coming to market.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel